Viral Infections in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

86 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-05-31

Study Completion Date

2009-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objectives of the study are

* to determine the prevalence of respiratory virus infections in COPD patients, during and outside acute exacerbation
* to explore the impact of these viral infections on the outcome of these patients
* to explore the association between blood procalcitonin levels and viral infections in this population.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity due to repeated exacerbations. The impact of viral infections during and outside COPD exacerbations is poorly understood and there is only scarce data on the role of new biological markers of infection for the management of COPD exacerbations.

Objectives of the project

The investigators aim to

1. describe the epidemiology of viral infections in patients admitted with an exacerbation of their COPD;
2. explore the evolution of viral infections outside exacerbations;
3. analyze the impact of viral infections on clinical outcomes;
4. explore the role of biological markers (CRP, procalcitonin) for the diagnosis and prognosis of viral infections.

Methods

The investigators will prospectively follow-up 100 patients admitted with an acute exacerbation of their COPD. Virological samples will be obtained at admission and at 3 months, to explore the evolution outside episodes of acute exacerbation. Clinical information will be obtained after one-year follow-up. Samples will be tested by RT-PCR for 15 respiratory viruses. The impact of viral infections and the role of biological markers will be explored using univariate and multivariate Cox proportional hazard models.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive Respiratory Tract Infections Virus Diseases Lung Diseases, Obstructive

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

procalcitonin acute exacerbation RT-PCR Biological Markers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All consecutive patients known or suspected for moderate to very severe COPD and admitted in the emergency center for an acute exacerbation of their COPD
* Age above 18 years
* We plan to include 100 patients with a complete work-up and follow-up
* Written informed consent will be obtained from every participant

Exclusion Criteria

* Patients requiring oro-tracheal intubation
* Patients unable to give their informed consent due to their clinical condition
* Other obvious cause of dyspnea (pulmonary embolism, acute pulmonary edema, lobar pneumonia)
* Patients suffering from bronchiectasis, asthma, pulmonary fibrosis and mineral dust pneumoconiosis
* Patients with a history of active tuberculosis
* Patients with a history of ischemic cerebral stroke and subsequent deglutition dysfunction

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

HUG, Geneva

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Olivier T Rutschmann, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Geneva

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Geneva University Hospital

Geneva, Canton of Geneva, Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Kherad O, Kaiser L, Bridevaux PO, Sarasin F, Thomas Y, Janssens JP, Rutschmann OT. Upper-respiratory viral infection, biomarkers, and COPD exacerbations. Chest. 2010 Oct;138(4):896-904. doi: 10.1378/chest.09-2225. Epub 2010 Apr 30.

Reference Type DERIVED

PMID: 20435659 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

06-257

Identifier Type: -

Identifier Source: org_study_id